RxDoctor Payments Data

Nita Rastogi, MD

Internal Medicine · Harrisburg, PANPI 1306827092

Payments from drug & device makers

$10,493in general payments, 2019–2025

Across 625 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$926
  • GSK$525
  • Corcept Therapeutics$513
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$10,463100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,493 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$44,810
Medicare patients
48
Services billed
687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$37,598
FarxigaDapagliflozin Propanediol27$31,399
XareltoRivaroxaban37$29,241
JanumetSitagliptin Phos/Metformin Hcl18$23,260
JardianceEmpagliflozin14$21,943
OzempicSemaglutide15$20,708
Xigduo XrDapaglifloz Propaned/Metformin11$18,495
JanuviaSitagliptin Phosphate14$11,655
TradjentaLinagliptin14$10,811
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl83$8,566
VascepaIcosapent Ethyl20$5,058
Atorvastatin Calcium241$3,452
Nebivolol Hcl27$2,888
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$2,586
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$449$37,59835 claims
MerckJanumet, Januvia$91$34,91432 claims
Boehringer IngelheimJardiance, Tradjenta$409$32,75428 claims
AstraZenecaFarxiga$1,249$31,39927 claims
Johnson & JohnsonXarelto$253$29,24137 claims
Novo NordiskOzempic$1,173$20,70815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →